



## Suggested Readings On Meningococcal Disease

Following are suggested readings for more information on meningococcal disease.

### **Meningococcal Disease in Adolescents and College Students**

- Centers for Disease Control and Prevention. Prevention and control of meningococcal disease: Recommendations of the Advisory Committee on Immunization Practices. *MMWR* 2005;54:RR-7.
- American Academy of Pediatrics Committee on Infectious Diseases. Prevention and control of meningococcal disease: Recommendations for use of meningococcal vaccines in pediatric patients. Policy statement. *Pediatrics*. 2005;116:496-505.
- Erickson LJ, De Wals P, McMahon J, et al. Complications of meningococcal disease in college students. *Clin Infect Dis*. 2001;33(5):737-739.
- Harrison LH, Pass MA, CIC MS, et al. Invasive meningococcal disease in adolescents and young adults. *JAMA*. 2001;286:694.
- Bruce MG, Rosenstein NE, Capparella JM, et al. Risk factors for meningococcal disease in college students. *JAMA*. 2001;286:688-693.
- Harrison LH. Preventing meningococcal infection in college students. *Clin Infect Dis*. 2000;30:648-651.
- Harrison LH, Dwyer DM, Maples CT, et al. Risk of meningococcal infection in college students. *JAMA*. 1999;281(20):1906-1910.
- National Foundation for Infectious Diseases. The changing epidemiology of meningococcal disease in the U.S. with an emphasis on college health issues. Summary of roundtable discussion, 1999.
- National Foundation for Infectious Diseases. The changing epidemiology of meningococcal disease among U.S. children, adolescents and young adults. NFID Continuing Medical Education Monograph, 2004.
- National Foundation for Infectious Diseases. Bridging from a strong childhood foundation to a healthy adulthood. NFID Continuing Medical Education Monograph, 2005.

### **Meningococcal Disease in Children**

- Pichichero M, Casey J, Blatter M, et al. Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children. *Pediatr Infect Dis J*. 2005 Jan;24(1):57-62.

### **Meningococcal Disease and Prevention**

- Rosenstein NE, Perkins, BA, Stephens DS, et al. Meningococcal disease. *N Engl J Med*. 2001;344:1378-1388.
- Perkins BA. New opportunities for prevention of meningococcal disease. *JAMA*. 2000;283(21):2842-2843.

- Maiden MCJ, Spratt BG. Meningococcal conjugate vaccines: new opportunities and new challenges. *Lancet*. 1999;354:615-616.

#### **Serogroup Distribution in the United States**

- Rosenstein NE, Perkins BA, Stephens DS, et al, and the Active Bacterial Core Surveillance Team. The changing epidemiology of meningococcal disease in the United States, 1992-1996. *J Infect Dis*. 1999;180:1894-1901.
- Centers for Disease Control and Prevention. Serogroup Y meningococcal disease – Illinois, Connecticut, and selected areas, United States, 1989-1996. *MMWR*. 1996;45(46):1010-1014.
- 
- Jackson LA, Schuchat A, Reeves MW, et al. Serogroup C meningococcal outbreaks in the United States: an emerging threat. *JAMA*. 1995;273:383-389.